Gaucher's Disease Type III FDA approvals, PDUFA dates and pipeline.
Updated Snapshot 20261116T222116ZBuilt
We track 1 Gaucher's Disease Type III drug. No FDA approvals recorded yet.
Drugs
| Drug | Sponsor | Modality | Designations |
|---|---|---|---|
| Cerezyme (imiglucerase) | SNY | biologic | — |
Upcoming catalysts
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Jan to Apr 2030Quarter disclosed | Cerezyme (imiglucerase) | SNY | Topline readout | Gaucher's Disease Type III | Scheduled | ClinicalTrials.gov |
| January 2030Month disclosed | Cerezyme (imiglucerase) | SNY | Primary completion | Gaucher's Disease Type III | Scheduled | ClinicalTrials.gov |
Past catalysts and decisions
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| October 2, 2025 | Cerezyme (imiglucerase) | SNY | Primary completion | Gaucher's Disease Type III | Completed | ClinicalTrials.gov |
All indications · Approval rates by indication
Not submitted to search engines: Needs 2 drugs and 3 sourced events; has 1 and 3.
Questions
What Gaucher's Disease Type III drugs have upcoming PDUFA dates?
None disclosed.
Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.